Tasosartan. Antihypertensive angiotensin II antagonist

Drugs of the Future

Volumn 22, Issue 8, 1997, Pages 850-855

  Merlos, M ^a   Casas, A ^b   Castaner J ^c  

^a UNIVERSITY OF BARCELONA   (Spain)

^b HOSPITAL CLÍNIC   (Spain)

^c PROUS SCIENCE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN II ANTAGONIST; ANTIHYPERTENSIVE AGENT; CAPTOPRIL; NICARDIPINE; TASOSARTAN;

BLOOD PRESSURE; CLINICAL TRIAL; DOSE RESPONSE; DRUG ACTIVITY; DRUG EFFICACY; DRUG SYNTHESIS; HUMAN; HYPERTENSION; NONHUMAN; ORAL DRUG ADMINISTRATION; RAT; SHORT SURVEY;

EID: 0030697427     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.1997.022.08.416896     Document Type: Short Survey

References (18)

1. Ellingboe, J.W., Antane, M., Nguyen, T.T. et al. Pyrido[2,3-p]pyrimidine angiotensin II antagonists. J Med Chem 1994, 37: 542-50.
2. Ellingboe, J.W., Nikaido, M., Bagli, J. (American Home Prods. Corp.). Substd. pyridopyrimidines useful as angiotensin II antagonists. EP 539086, US 5149699, US 5256654.
3. Giguere, P., Iera, S., Bernatchez, M., Barreca, G., Castaldi, G., Cannata, V. (American Home Prods. Corp.). Process for preparation of biphenyl derivs. WO 9640684.
4. Casas, A., Merlos, M., Castañer, J. Irbesartan. Drugs Fut 1997, 22: 481-91.
5. Park, C.H., Ellingboe, J., Collini, M., Nguyen, T., Bagli, J., Russo, A., Hartupee, D., Oshiro, G., Colatsky, T.J. WAY-ANA-756, a new AT1-selective nonpeptidic angiotensin II (AII) receptor antagonist. FASEB J 1994, 8(4, Part 1): Abst 23.
6. Chen, L.-S.K., Ling, H.-P., Cuddy, M., Colatsky, T.J. Pharmacological characterization of two new angiotensm II receptor antagonists, WAY-126227 and WAY-126756. Circulation 1993, 88(4, Suppl. 2): Abst 2330.
7. Hartupee, D., White, V., Rovnyak, L. et al. In vivo characterization of WAY ANA-756, an angiotensin II (AII) antagonist. FASEB J 1994, 8(4, Part 1): Abst 24.
8. Haskins, J.T., Morris, H., Boast, C.A. Effecfs of a novel angiotensin II antagonist, ANA-756, on radial maze performance in rats. Soc Neurosci Abst 1995, 21 (Part 1): Abst 71.1.
9. Klamerus, K.J., Vadiei, K., Burghart, P., Neefe, D.L., Zimmerman, J.J. Ascending single-dose, safety, tolerance, and pharmacokinetics (PK) of 5,8-dihydro-2,4-dimethyl-8-[(2′-(1H-tetrazol-5-yl)[1,1′ - biphenyl, - 4 - yl) methyl]pyrido[2,3 - d]pyrimidin -7(6H)-one (ANA-756). Clin Pharmacol Ther 1995, 57(2): Abst PIII-35.
10. Neefe, D.L., Klamerus, K.J., Battle, M.M., Mayer, P.R. Multiple dose safety, pharmacokinetic (PK) and pharmacodynamic study of tasosartan in patients with mild to moderate hypertensIOn. Amer J Hypertension 1997, 10(4, Part 2): 105A.
11. Neefe, D.L., Battle, M.M., Klamerus, K.J., Mayer, P.P., Stoltz, R., Whitehead, B.F., Burghart, P.H. Tasosartan and nicardipine interaction in patients with essential hypertension. Amer J Hypertension 1997, 10(4, Part 2): 105A.
12. Battle, MM., Klamerus, K.J., Klockowski, P.M., Whitehead, B.F., Neefe, D.L., Mayer, P.R. Effects of tasosartan and glyburide coadministration in patents with noninfulin-dependent diabetes mellitus. Amer J Hypertension 1997, 10(4, Part 2): 118A.
13. Steinhäuslin, F., Buclin, T., Bouissou, P., Verejan, I., Nussberqer, J., Tournadre, P.H., Vadiei, K., Brunner, H.R., Biollaz, J. Angiotensin II (AII) blockade effect of ANA-756 in normal volunteers. Clin Pharmacol Ther 1994, 55(2): Abst PIII-92.
14. Himmelmann, A., Petterson, A., Bergbrant, A., Svensson, A., Bouissou, P., Häss, G., Yateman, N., Hedner, J., Hedner, T. Efficacy and safety of tasosartan (ANA-756) - A new angiotensin II antagonist. J Hypertension 1996, 14(Suppl. 1): Abst P961.
15. Bergbrant, A., Svensson, A., Himmelmann, A., Pettersson, A., Bouissou, P., Häss, G., Yateman, N., Hedner, J., Hedner, T. Tasosartan (ANA-756) a new angiotensin II antagonist in hypertension. 6th Int Cong Cardiovasc Pharmacother (Feb 26-29, Sydney) 1996, A18.
16. Lacourciere, Y., Poirier, L. Tasosartan: A once-a-day angiotensin II (AII) receptor antagonist with a documented dose-response. Amer J Hypertension 1997, 10(4, Part 2): 116A.
17. Neutel, J.M., Smith, D.H.G., Weber, M.A. Efficacy and tolerability of tasosartan, a novel angiotensin II antagonist: Results from a 10-week double-blind, placebo-controlled, dose-titration study. Amer J Hypertension 1997, 10(4, Part 2): 77A.
18. Klamerus, K.J., Battle, M.M., Burghart, P.R., Whitehead, B.F., Neefe, D.L., Fruncillo, R.J., Weinryb, I., Mayer, P.R. Effects of concomitant tasosartan and HCTZ administration in healthy volunteers. Amer J Hypertension 1997, 10(4, Part 2): 118A.